Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-28T06:14:55.989Z Has data issue: false hasContentIssue false
  • English
  • Français

Selective reporting of pharmaceutical data leads major medical journals to change editorial policy

Published online by Cambridge University Press:  21 May 2015

Tom Perry
Tom Perry*
Affiliation:
Departments of Medicine and Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC
*
Department of Medicine, University Hospital, 2211 Wesbrook Mall, Vancouver BC V6T 2B5; tperryjr@interchange.ubc.ca

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Controversies • Controverses
Information
Canadian Journal of Emergency Medicine , Volume 3 , Issue 4 , October 2001 , pp. 321 - 322
Copyright
Copyright © Canadian Association of Emergency Physicians 2001

References

1.Silverstein, FE, Faich, G, Goldstein, JL, Simon, LS, Pincus, T, Whelton, A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247–55.Google Scholar
2.Bombardier, C, Laine, L, Reicin, A, Shapiro, D, Burgos-Vargas, R, Davis, B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR [Vioxx Gastrointestinal Outcomes Research] study group. N Engl J Med 2000;343:1520–8.Google Scholar
3.Mukherjee, D, Nissen, SE, Topol, EJ.Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8):954–9.Google Scholar
4.Okie, S.Missing data on Celebrex: Full study altered picture of drug. Washington Post 2001 Aug 5; Sect A:11.Google Scholar
5.Lichtenstein, DR, Wolfe, MM.COX-2–selective NSAIDs: New and improved? [editorial]. JAMA 2000;284(10):1297–9.Google Scholar
6.Davidoff, F, DeAngelis, CD, Drazen, JM, Nicholls, MG, Hoey, J, Hojgaard, L, et al. Sponsorship, authorship and accountability. CMAJ 2001;165(6):786–8.Google Scholar
7.Yusef, S, Sleight, P, Pogue, J.Bosch, J, Davies, R, Dagenais, G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53.Google Scholar